Sanofi successfully prices EUR 1 billion bond issue
29 August 2013 | By Sanofi
Sanofi announces that it has successfully priced its offering of EUR 1 billion of notes, due 2020, bearing interest at an annual rate of 1.875%...
List view / Grid view
News
Scientists succeed in growing human brain tissue in “test tubes”
28 August 2013 | By IMBA - Institute of Molecular Biotechnology GmbH
Complex human brain tissue has been successfully developed in a three-dimensional culture system established in an Austrian laboratory...
New carbon footprint tool launched to calculate the carbon footprint of pharmaceutical products
28 August 2013 | By Carbon Trust
ABPI collaborates with the Carbon Trust to help pharmaceutical companies quickly estimate the carbon footprint of tablet medicines distributed in blister packs...
Amgen to highlight new data at upcoming ESC Congress 2013
27 August 2013 | By Amgen
Amgen will present new data on omecamtiv mecarbil, a small molecule cardiac myosin activator that is being studied for the treatment of heart failure in collaboration with Cytokinetics...
ESC Congress 2013: New data provide evidence for the positive safety and efficacy profile of Pradaxa® in various atrial fibrillation patient populations
26 August 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announced the upcoming presentation of new data on the novel oral anticoagulant (NOAC) Pradaxa® (dabigatran etexilate) during the ESC Congress 2013...
Sanofi Pasteur’s Fluzone High-Dose vaccine significantly more effective than standard dose Fluzone vaccine in preventing influenza
26 August 2013 | By Sanofi Pasteur
“We are pleased that this study demonstrates the superior relative efficacy of Fluzone High-Dose vaccine..."
Novartis holds annual healthcare entrepreneur competition to generate insight into healthcare and innovation of tomorrow
26 August 2013 | By Novartis
Novartis has invited 60 selected students from leading international universities in 21 countries to its headquarters in Switzerland for the International Biotechnology Leadership Camp...
MedImmune strengthens immune-mediated cancer therapy portfolio with acquisition of Amplimmune
26 August 2013 | By AstraZeneca
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a definitive agreement to acquire Amplimmune...
Amgen to acquire Onyx Pharmaceuticals for $125 per share in cash
25 August 2013 | By Amgen
Amgen will acquire all of the outstanding shares of Onyx for $125 per share in cash...
GSK announces phase III study of vercirnon in patients with moderate-to-severe Crohn’s disease did not meet its primary endpoint
23 August 2013 | By GlaxoSmithKline
The first of four Phase III studies, the SHIELD-1 study, investigating vercirnon in adult patients with moderately-to-severely active Crohn’s disease did not achieve the primary endpoint...
Abbott-sponsored session gets to grips with being 60 at FOCUS 2013
21 August 2013 | By kdm communications limited
Corresponding with the 60th Anniversary of the Association for Clinical Biochemistry, Abbott recently hosted an enthusiastically received session at the Annual ACB FOCUS National Meeting held in York, entitled The Diamond Generation; Pathology begins at 60...
Abbott completes acquisition of IDEV Technologies
21 August 2013 | By Abbott
Abbott has completed its acquisition of IDEV Technologies, a privately held company focused on developing next-generation medical devices...
5 steps to complete confidence in your balance purchase
20 August 2013 | By METTLER TOLEDO
Whether you work with simple or complex samples, guaranteeing the correct results is important...
Novartis receives FDA breakthrough therapy designation for BYM338 (bimagrumab) for sporadic inclusion body myositis (sIBM)
20 August 2013 | By Novartis
Novartis announced that the US FDA has granted breakthrough therapy designation to BYM338 for sporadic inclusion body myositis (sIBM)...
GSK receives EMA approval for new Tyverb® (lapatinib) indication in combination with trastuzumab
19 August 2013 | By Packer Forbes Communications
The EMA has granted an update to the marketing authorisation for Tyverb® (lapatinib) to be used in combination with Herceptin® (trastuzumab)...
